Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC)

Next Previous
Trial Profile

A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bexotegrast (Primary)
  • Indications Hepatic fibrosis; Primary sclerosing cholangitis
  • Focus Adverse reactions
  • Acronyms INTEGRIS-PSC
  • Sponsors Pliant Therapeutics

Most Recent Events

  • 18 Nov 2024 According to a Pliant Therapeutics media release, company announced the presentation of clinical data of this study at The Liver Meeting 2024 of the American Association for the Study of Liver Diseases (AASLD) being held in San Diego, California.
  • 17 Oct 2024 According to a Pliant Therapeutics media release, 24 week result from the INTEGRIS-PSC Phase 2a trial of bexotegrast will be presented at The Liver Meeting 2024 of the American Association for the Study of Liver Diseases (AASLD), in San Diego, California November 15-19.
  • 10 Sep 2024 According to a Pliant Therapeutics media release, integrated safety summary of bexotegrast from the INTEGRIS-IPF and INTEGRIS-PSC were presented at the European Respiratory Society (ERS) International Congress 2024 taking place in Vienna, Austria September 7-11, 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top